Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry.

Dora V StölzlNicole SanderAnnice HeratizadehEva HaufeInken HarderSusanne AbrahamLuise HeinrichAndreas KleinheinzAndreas WollenbergElke WeisshaarKnut SchäkelKonstantin ErtnerFranca WiemersJulia WildbergerMargitta WormRalph von KiedrowskiIsaak EffendyAndrea AsmussenMatthias AugustinMario PawlakMichael Sticherling Alexander ZinkMelanie HilgersChristiane HandrickSven QuistBeate SchwarzPetra Staubach-RenzMagnus BellSun-Hei Hong-WeldemannBernhard HomeyJens-Joachim BrücherJochen SchmittThomas WerfelStephan Weidingernull null

Published in: The British journal of dermatology (2022)

This interim analysis from the atopic dermatitis registry TREATgermany shows robust long-term efficacy, favourable safety and high persistence of dupilumab under real life conditions.

Keyphrases

atopic dermatitis
randomized controlled trial
systematic review
electronic health record
emergency department
big data
adverse drug